| Active substance | ravalizumab |
| Holder | Alexion Pharma Belgium |
| Status | Running |
| Indication | the treatment of atypical Haemolytic Uremic Syndrome in patients who completed the Open Label Extension of the phase III studies ALXN1210-aHUS-311 and ALXN1210-aHUS-312 (EudraCT Nr: 2016-002027-29) and ALXN1210-aHUS-312 (EudraCT Nr: 2016-002499-29) |
| Public documents | Approbation |
| Information for the patient | |
| Informed consent | |
| Last update | 10/07/2023 |